Sulfasalazine

CAS No. 599-79-1

Sulfasalazine ( Azopyrin; NSC 203730; NSC 667219 )

Catalog No. M15233 CAS No. 599-79-1

Sulfasalazine, a sulfa agent and a derivative of mesalazine, is used primarily as an anti-inflammatory agent.

Purity : >98%(HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
500MG 41 In Stock
1G 48 In Stock

Biological Information

  • Product Name
    Sulfasalazine
  • Note
    Research use only, not for human use.
  • Brief Description
    Sulfasalazine, a sulfa agent and a derivative of mesalazine, is used primarily as an anti-inflammatory agent.
  • Description
    Sulfasalazine, a sulfa agent and a derivative of mesalazine, is used primarily as an anti-inflammatory agent. Target: Others Sulfasalazine (Azulfidine), used to treat pain and swelling in arthritis, belongs to a class of drugs called sulfa drugs.
  • Synonyms
    Azopyrin; NSC 203730; NSC 667219
  • Pathway
    Chromatin/Epigenetic
  • Target
    COX
  • Recptor
    COX-1; COX-2; NF-κB
  • Research Area
    Inflammation/Immunology
  • Indication
    ——

Chemical Information

  • CAS Number
    599-79-1
  • Formula Weight
    398.39
  • Molecular Formula
    C18H14N4O5S
  • Purity
    >98%(HPLC)
  • Solubility
    DMSO: 80 mg/mL (200.8 mM)
  • SMILES
    O=C(O)C1=CC(/N=N/C2=CC=C(S(=O)(NC3=NC=CC=C3)=O)C=C2)=CC=C1O
  • Chemical Name
    (E)-2-hydroxy-5-((4-(N-(pyridin-2-yl)sulfamoyl)phenyl)diazenyl)benzoic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Weber CK, et al. Gastroenterology. 2000 Nov;119(5):1209-18.
molnova catalog
related products
  • Phenetidine

    Used in the manufacture of acetophenetidin.

  • Bromfenac sodium

    Bromfenac Sodium is the sodium salt form of bromfenac, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and anti-inflammatory activities.

  • Pamicogrel

    Pamicogrel is an inhibitor of COX. Pamicogrel has platelet anti-aggregatory properties which is under development by Kanebo for chronic arterial occlusion.